



US009636418B2

(12) **United States Patent**  
**Murray et al.**

(10) **Patent No.:** **US 9,636,418 B2**  
(45) **Date of Patent:** **\*May 2, 2017**

(54) **POTENT AND SELECTIVE INHIBITORS OF NA<sub>v</sub>1.7**(71) Applicant: **AMGEN INC.**, Thousand Oaks, CA (US)(72) Inventors: **Justin K. Murray**, Moorpark, CA (US); **Jerry Ryan Holder**, Simi Valley, CA (US); **Malgorzata Wanska**, Camarillo, CA (US); **Christopher M. Tegley**, Thousand Oaks, CA (US); **James R. Falsey**, Moorpark, CA (US); **Elizabeth M. Doherty**, Thousand Oaks, CA (US); **Leslie P. Miranda**, Thousand Oaks, CA (US)(73) Assignee: **AMGEN INC.**, Thousand Oaks, CA (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/207,445**(22) Filed: **Mar. 12, 2014**(65) **Prior Publication Data**

US 2015/0023988 A1 Jan. 22, 2015

**Related U.S. Application Data**

(60) Provisional application No. 61/778,331, filed on Mar. 12, 2013.

(51) **Int. Cl.**

<b>C07K 14/435</b>	(2006.01)
<b>A61K 47/48</b>	(2006.01)
<b>C07K 16/44</b>	(2006.01)
<b>C07K 14/705</b>	(2006.01)
<b>A61K 38/00</b>	(2006.01)

(52) **U.S. Cl.**

CPC ..	<b>A61K 47/48438</b> (2013.01); <b>A61K 47/48215</b> (2013.01); <b>A61K 47/48369</b> (2013.01); <b>C07K 14/43518</b> (2013.01); <b>C07K 14/705</b> (2013.01); <b>C07K 16/44</b> (2013.01); <b>A61K 38/00</b> (2013.01)
--------	--

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

## U.S. PATENT DOCUMENTS

5,672,688 A	9/1997	Kobayashi et al.
5,756,663 A	5/1998	Lampe et al.
5,877,026 A	3/1999	Lampe
5,968,838 A	10/1999	Lampe et al.
6,670,329 B2	12/2003	Song-Ping
7,125,676 B2	10/2006	George, Jr. et al.
7,125,847 B1	10/2006	Sachs et al.
7,132,505 B1	11/2006	Lazdunski et al.
7,259,145 B2	8/2007	Sachs et al.

7,375,234 B2	5/2008	Sharpless et al.
7,393,657 B2	7/2008	Diss et al.
7,396,816 B2	7/2008	Yokotagawa et al.
7,485,449 B2	2/2009	Rouleau et al.
7,528,093 B2	5/2009	Rouleau et al.
7,531,523 B2	5/2009	McCormack et al.
7,705,055 B2	4/2010	Ehring et al.
7,759,078 B2	7/2010	Djamgoz et al.
7,763,736 B2	7/2010	Sharpless et al.
7,767,718 B2	8/2010	Ehring et al.
7,972,813 B2	7/2011	McCormack et al.
8,372,396 B2	2/2013	Andya et al.
8,399,026 B2	3/2013	Meir et al.
9,279,003 B2	3/2016	Park et al.
9,340,590 B2	5/2016	Murray et al.
2004/0146877 A1	7/2004	Diss et al.
2004/0248207 A1	12/2004	Okuse et al.
2005/0137190 A1	6/2005	Gonzalez, III et al.
2005/0187217 A1	8/2005	Wilson et al.
2006/0025415 A1	2/2006	Gonzalez, III et al.
2006/0160817 A1	7/2006	Martinborough et al.
2009/0074665 A1	3/2009	Diss et al.
2010/0273866 A1	10/2010	Diss et al.
2011/0065647 A1	3/2011	Meir et al.

(Continued)

## FOREIGN PATENT DOCUMENTS

CN	100429229 C	10/2008
CN	101428138 A	5/2009

(Continued)

## OTHER PUBLICATIONS

Ahmad, et al. "A Stop Codon Mutation in SCN9A Causes Lack of Pain Sensation", *Human Molecular Genetics*; 16(17): 2114-2121 (2007).Amaya, et al., The Voltage-Gated Sodium Channel NA,1.9 is an Effector of Peripheral Inflammatory Pain Hypersensitivity *J Neurosci* 26(50):12852-12860 (2006).Black, et al., "Expression of Nav1.7 in DRG Neurons extends from Peripheral Terminals I the Skin to Central Preterminal Branches and Terminals in the Dorsal Horn"; *Molecular Pain*, 8:82, doi:01.1186/1744-8069-8-82 (2012).Bolcskei, et al., "Voltage-Gated Sodium Channel Blockers, 2001-2006: An Overview"; *Medicinal Chemistry Research*; 17: 356-368 (2008).Bosmans, et al., "Four Novel Tarantula Toxins as Selective Modulators of Voltage-Gated Sodium Channel Subtypes"; *Molecular Pharmacology*; 69: 419-429 (2006).Bregman, et al., "Identification of a Potent, State-Dependent Inhibitor of Nav1.7 with Oral Efficacy in the Formalin Model of Persistent Pain"; *Journal of Medicinal Chemistry*; 54: 4427-4445 (2011).

(Continued)

Primary Examiner — Lianko Garyu

(74) Attorney, Agent, or Firm — Angela L. Purcell

(57) **ABSTRACT**Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Na<sub>v</sub>1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Na<sub>v</sub>1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.